Nanoparticle-based passive drug targeting to tumors: Considerations and implications for optimization

Ken-ichi Ogawara, Yuta Yoshizawa, Keita Un, Tomoya Araki, Toshikiro Kimura, Kazutaka Higaki

Research output: Contribution to journalReview articlepeer-review

15 Citations (Scopus)


There are many potential barriers to the effective delivery of small-molecule drugs to solid tumors. Most small-molecule chemotherapeutic drugs have a large volume of distribution upon intravenous administration, which is often associated with a narrow therapeutic index due to their high level of toxicity in healthy tissues. Nanoparticle-based therapeutics for tumor targeting have emerged as one of the promising approaches to overcome the lack of tissue specificity of conventional chemotherapeutic drugs. Various different concepts have been envisioned for nanoparticle-mediated drug targeting. Among them, the passive drug targeting strategy has been the most widely investigated, and numerous preclinical studies have provided insights into the validity of the strategy. This review article briefly introduces our recent findings related to the passive drug targeting strategy including its application in anti-angiogenic therapy, along with considerations to be taken into account and implications for the rational design of a passive drug targeting strategy.

Original languageEnglish
Pages (from-to)698-702
Number of pages5
JournalBiological and Pharmaceutical Bulletin
Issue number5
Publication statusPublished - May 2013


  • Angiogenesis
  • Anti-cancer drug
  • Endothelial cell
  • Nanoparticle
  • Passive targeting

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science


Dive into the research topics of 'Nanoparticle-based passive drug targeting to tumors: Considerations and implications for optimization'. Together they form a unique fingerprint.

Cite this